Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND)

Vyome (NASDAQ:HIND)‘s stock had its “buy” rating reaffirmed by Maxim Group in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. They currently have a $15.00 price objective on the stock. Maxim Group’s target price would indicate a potential upside of 172.23% from the company’s current price.

HIND has been the topic of a number of other reports. Citigroup upgraded shares of Vyome to a “buy” rating in a research note on Thursday. Wall Street Zen cut shares of Vyome from a “hold” rating to a “sell” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.00.

Vyome Trading Up 2.8%

NASDAQ:HIND opened at $5.51 on Thursday. Vyome has a twelve month low of $5.04 and a twelve month high of $720.00. The stock has a market capitalization of $3.69 million, a P/E ratio of -0.01 and a beta of 1.05.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.